Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter 2013
Date:8/6/2013

er.  Our recent successful stock offering provides us with the cash we need to develop ISIS-APOCIIIRx through Phase 3 development on our own.  Already this year, we reported positive Phase 2 data from ISIS-APOCIIIRx in two separate Phase 2 studies in patients with high triglycerides.
In these studies, we observed positive effects on apoC-III, triglycerides, overall lipid parameters and other measures of activity.  These data show that ISIS-APOCIIIRx can be used as a monotherapy or in combination with other triglyceride-lowering drugs with the potential to positively impact the lives of patients with severely high triglycerides.  We plan to report the third set of data later this month and initiate the Phase 3 program for ISIS-APOCIIIRx early next year after discussions with the FDA and European regulators," concluded Ms. Parshall.

Drug Development Highlights

  • Isis and its partners advanced antisense drugs in Isis' pipeline and reported positive clinical data from three programs.
  • Isis advanced the Phase 2/3 study of ISIS-TTRRx, a drug to treat patients with familial amyloid polyneuropathy.  As a result, Isis earned $2 million from GlaxoSmithKline.
  • Isis reported Phase 2 data on ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable fibrates.  In this study, ISIS-APOCIIIRx treatment resulted in statistically significant reductions in triglycerides and apoC-III and a statistically significant increase in HDL.
  • Isis reported Phase 2 data on ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes at the American Diabetes Association Scientific Sessions.  In this study, ISIS-APOCIIIRx treatment resulted in statistically significant reductions in triglycerides and apoC-III and a statistically significant increase in high-density lipoprotein (HDL).  In this
    '/>"/>

  • SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. CVS Caremark Reports Record Second Quarter Results
    2. BioLineRx Reports Second Quarter 2013 Results
    3. Regeneron Reports Second Quarter 2013 Financial and Operating Results
    4. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
    5. Volcano Reports Second Quarter Results; Medical Segment Revenues Increase More Than 13 Percent On A Constant Currency Basis
    6. Landauer, Inc. Reports Fiscal 2013 Third Quarter Results
    7. PDI Reports 2013 Second Quarter Financial Results
    8. U.S. Orthopedic Biomaterials Market & Global Biomaterials Industry Reviewed by Products and Applications in New Research Reports
    9. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
    10. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
    11. Neuland Labs Reports First Quarter Fiscal Year 2014 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" report ... was approved by CFDA to treat wet age- related ... product of Novartis, is available in the Chinese market. ... drug for the treatment of wet AMD in ...
    (Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
    (Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
    Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
    ... VIEW, Calif., Jan. 21, 2011 VIVUS, Inc. (Nasdaq: ... meeting with the Food and Drug Administration (FDA) for the ... the treatment of obesity.  The meeting occurred on January 19th ... senior members of the FDA and VIVUS, management and consultants. ...
    ... Initiatives, Inc. (Nasdaq: MTXX ) ("Matrixx" or ... markets Zicam® products, today provided a summary of the ... of Merger, dated as of December 14, 2010, by ... Holdings Acquisition Corp. (the "Merger Agreement").  Pursuant to the ...
    Cached Medicine Technology:VIVUS Provides Regulatory Update on QNEXA NDA 2VIVUS Provides Regulatory Update on QNEXA NDA 3Matrixx Initiatives, Inc. Summarizes Ongoing 'Go-Shop' Process and Board Reaffirms Recommendation 2Matrixx Initiatives, Inc. Summarizes Ongoing 'Go-Shop' Process and Board Reaffirms Recommendation 3Matrixx Initiatives, Inc. Summarizes Ongoing 'Go-Shop' Process and Board Reaffirms Recommendation 4Matrixx Initiatives, Inc. Summarizes Ongoing 'Go-Shop' Process and Board Reaffirms Recommendation 5
    (Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris ... college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio ... expand its reach and impact through innovative technologies and strategies. , “I am very ...
    (Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , ... 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park ...
    (Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
    (Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
    (Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
    Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
    ... until it encounters a cancer cell, then suddenly activates and ... marks the latest step in scientists, efforts to tap the ... of the technology at the University of Rochester Medical Center ... machines produced in abundance by tumors to chew through and ...
    ... a major public health problem through its association with ... life expectancy rises around the world, along with the ... incidence of hip fractures is estimated to reach 6.3 ... of fracture in men and women. A new review ...
    ... on the words ,light, and ,mild, smokers in Western ... may be less harmful than others. In fact, ... of risk to smokers, including ,mild, and ,low-tar, brands. ... Addiction polled over 8000 smokers from Australia, Canada, ...
    ... Amanda Gardner HealthDay Reporter , MONDAY, April 11 ... primary care doctors often choose a different option than they ... In fact, physicians who were surveyed in the research more ... to have long-term repercussions, such as paralysis, than to die. ...
    ... University researcher has co-authored an international study that revealed a ... treat a rare lung disease in women. The life-threatening ... The clinical trial of the drug -- called sirolimus ... a therapy for the lung disease, lymphangioleiomyomatosis, or LAM. ...
    ... -- Long-term use of antibiotics to treat acne doesn,t ... medications, a new study finds. The finding came ... of antibiotics has been credited with encouraging antibiotic resistance ... Pennsylvania School of Medicine assessed the prevalence of ...
    Cached Medicine News:Health News:A 'Pacman strategy' to boost the immune system to fight cancer 2Health News:A 'Pacman strategy' to boost the immune system to fight cancer 3Health News:Changing trends in hip fracture incidence around the world 2Health News:Smokers believe 'silver', 'gold' and 'slim' cigarettes are less harmful 2Health News:Doctors Often Wouldn't Follow Their Own Advice: Study 2Health News:Doctors Often Wouldn't Follow Their Own Advice: Study 3Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Acne Antibiotics Not Linked to Drug Resistance 2
    ... most comprehensive family of lightweight standard ... incision, Glaucoma filtration, and Vitreoretinal uses. ... with minimal tissue trauma and minimal ... are available in 18, 20, and ...
    ... offers the most comprehensive family of ... for Cataract incision, Glaucoma filtration, and ... is achieved with minimal tissue trauma ... eraser styles are available in 18, ...
    ... most comprehensive family of lightweight standard ... incision, Glaucoma filtration, and Vitreoretinal uses. ... with minimal tissue trauma and minimal ... are available in 18, 20, and ...
    ... Medtronic Ophthalmics offers the most ... specialty Eraser Instruments for Cataract incision, ... and discrete coagulation is achieved with ... cellular necrosis. Straight eraser styles are ...
    Medicine Products: